Xiangxue Pharmaceutical Market Cap ($469.31 Million)
Market Cap & Net Worth: Xiangxue Pharmaceutical (300147)
Xiangxue Pharmaceutical market cap. Xiangxue Pharmaceutical (SHE:300147) has a market capitalization of $469.31 Million (CN¥3.21 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #12282 globally and #3583 in its home market, demonstrating a -8.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xiangxue Pharmaceutical's stock price CN¥4.85 by its total outstanding shares 661279045 (661.28 Million). Also see cash flow conversion of Xiangxue Pharmaceutical for how efficiently the company converts equity into cash flow.
Xiangxue Pharmaceutical Market Cap History (2015–2026)
Xiangxue Pharmaceutical market cap history from 2015 to 2026. Data shows change from $2.37 Billion to $469.31 Million (-12.05% CAGR). Check latest Xiangxue Pharmaceutical stock price today for real-time trading data and today's change.
Xiangxue Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xiangxue Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Xiangxue Pharmaceutical (300147) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.55x
Xiangxue Pharmaceutical's market cap is 0.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.23 Billion | $1.86 Billion | $66.02 Million | 0.66x | 18.63x |
| 2017 | $855.51 Million | $2.19 Billion | $65.94 Million | 0.39x | 12.97x |
| 2018 | $588.07 Million | $2.50 Billion | $56.44 Million | 0.23x | 10.42x |
| 2019 | $853.35 Million | $2.79 Billion | $76.51 Million | 0.31x | 11.15x |
| 2020 | $866.05 Million | $3.07 Billion | $98.42 Million | 0.28x | 8.80x |
| 2021 | $780.90 Million | $2.97 Billion | -$688.47 Million | 0.26x | N/A |
| 2022 | $587.37 Million | $2.19 Billion | -$530.06 Million | 0.27x | N/A |
| 2023 | $498.34 Million | $2.30 Billion | -$388.96 Million | 0.22x | N/A |
| 2024 | $945.40 Million | $1.86 Billion | -$858.56 Million | 0.51x | N/A |
| 2025 | $880.57 Million | $1.60 Billion | -$1.39 Billion | 0.55x | N/A |
Competitor Companies of 300147 by Market Capitalization
Companies near Xiangxue Pharmaceutical in the global market cap rankings as of November 6, 2026. Also see Xiangxue Pharmaceutical balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Xiangxue Pharmaceutical by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Xiangxue Pharmaceutical (2015–2026)
Market capitalization of Xiangxue Pharmaceutical from 2015 to today. Between 2015 and today, Xiangxue Pharmaceutical's market cap moved from $2.37 Billion to $ 469.31 Million, with a yearly change of -12.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥469.31 Million | -46.70% |
| 2025 | CN¥880.57 Million | -6.86% |
| 2024 | CN¥945.40 Million | +89.71% |
| 2023 | CN¥498.34 Million | -15.16% |
| 2022 | CN¥587.37 Million | -24.78% |
| 2021 | CN¥780.90 Million | -9.83% |
| 2020 | CN¥866.05 Million | +1.49% |
| 2019 | CN¥853.35 Million | +45.11% |
| 2018 | CN¥588.07 Million | -31.26% |
| 2017 | CN¥855.51 Million | -30.47% |
| 2016 | CN¥1.23 Billion | -47.99% |
| 2015 | CN¥2.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Xiangxue Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $469.31 Million USD |
| MoneyControl | $469.31 Million USD |
| MarketWatch | $469.31 Million USD |
| marketcap.company | $469.31 Million USD |
| Reuters | $469.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sa… Read more